Propulsive efficiency gains could diminish for bigger turbofans unless nacelle drag can be reduced. Flight tests show promise from a short inlet design.
Vertical Aerospace has completed initial tethered hover testing of a full-scale demonstrator for its VX4 electric vertical takeoff and landing air taxi.
The return of more long-haul flying will help boost Rolls-Royce average shop-visit volume in the low double digits for the next few years, the company projects.
Executives of aero-engine manufacturer Rolls-Royce say they are encouraged by increasing levels of flying activity, bolstered by domestic flights using wide-body aircraft.
Rolls-Royce's Power Generation System 1 (PGS1) demonstrator is designed to pave the way for future hybrid-electric regional propulsion system development.
Rolls-Royce says it will make its all of its civil aircraft engines compatible with sustainable aviation fuels (SAF) as part of its roadmap for decarbonizing aerospace.
The United deal, which also covers options for 35 additional aircraft, envisages introduction of the first civil supersonic services on trans-Atlantic and Pacific routes by 2029.
Following a series of commissioning runs with a Trent XWB turbofan and after almost three years of construction, Rolls-Royce has officially opened Testbed 80 at its Derby, England headquarters.
The agreement would clarify the manufacturer’s positions on using third-party alternatives such as parts repairs on its engines, and what, if any, ramifications such cost-saving moves have on warranties and other services.
As Boeing is quietly beginning to work on what is now being called the -5X project—a small widebody aircraft derived from the new mid-market airplane (NMA) studies—things are getting serious for the three engine OEMs, too.
The Norwegian government has prohibited the sale of Rolls-Royce's marine powerplant division Bergen Engines to the international arm of a Russian company.
Rolls-Royce CEO Warren East said he is confident about a rapid recovery of the air transport sector after the pandemic led the company to a £4 billion ($5.6 billion) loss in 2020.